Northern Trust
AQST icon

Northern Trust’s Aquestive Therapeutics AQST Stock Holding History

Northern Trust’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.04M Sell
732,504
-10,290
-1% -$41.8K ﹤0.01% 2736
2025
Q4 		$4.8M Buy
742,794
+59,926
+9% +$373K ﹤0.01% 2499
2025
Q3 		$3.82M Buy
682,868
+38,949
+6% +$168K ﹤0.01% 2666
2025
Q2 		$2.13M Buy
643,919
+56,091
+10% +$161K ﹤0.01% 2942
2025
Q1 		$1.7M Sell
587,828
-11,984
-2% -$36.3K ﹤0.01% 3002
2024
Q4 		$2.14M Buy
599,812
+18,199
+3% +$83.9K ﹤0.01% 2990
2024
Q3 		$2.9M Buy
581,613
+387,589
+200% +$1.51M ﹤0.01% 2772
2024
Q2 		$504K Buy
194,024
+96,104
+98% +$321K ﹤0.01% 3507
2024
Q1 		$417K Buy
97,920
+6,728
+7% +$22.4K ﹤0.01% 3622
2023
Q4 		$184K Buy
91,192
+25,692
+39% +$45.4K ﹤0.01% 3927
2023
Q3 		$100K Hold
65,500
– – ﹤0.01% 4014
2023
Q2 		$108K Buy
65,500
+5,672
+9% +$10.3K ﹤0.01% 4017
2023
Q1 		$68.2K Sell
59,828
-2,262
-4% -$1.96K ﹤0.01% 4183
2022
Q4 		$56K Hold
62,090
– – ﹤0.01% 4258
2022
Q3 		$73K Buy
62,090
+14,541
+31% +$16.4K ﹤0.01% 4213
2022
Q2 		$30K Sell
47,549
-10
-0% -$13 ﹤0.01% 4553
2022
Q1 		$124K Buy
47,559
+10
+0% +$29 ﹤0.01% 4284
2021
Q4 		$185K Buy
47,549
+1,820
+4% +$9.13K ﹤0.01% 4221
2021
Q3 		$199K Buy
45,729
+275
+0.6% +$1.08K ﹤0.01% 4181
2021
Q2 		$181K Sell
45,454
-166,948
-79% -$667K ﹤0.01% 4195
2021
Q1 		$1.1M Sell
212,402
-13,202
-6% -$70.2K ﹤0.01% 3547
2020
Q4 		$1.21M Sell
225,604
-6,299
-3% -$37.8K ﹤0.01% 3440
2020
Q3 		$1.13M Sell
231,903
-5,852
-2% -$38.3K ﹤0.01% 3347
2020
Q2 		$1.16M Buy
237,755
+190,451
+403% +$877K ﹤0.01% 3305
2020
Q1 		$104K Buy
47,304
+33,327
+238% +$127K ﹤0.01% 3807
2019
Q4 		$81K Sell
13,977
-826
-6% -$4.3K ﹤0.01% 3969
2019
Q3 		$47K Sell
14,803
-83,839
-85% -$314K ﹤0.01% 4056
2019
Q2 		$414K Sell
98,642
-7,628
-7% -$39.1K ﹤0.01% 3607
2019
Q1 		$734K Buy
106,270
+48,201
+83% +$338K ﹤0.01% 3446
2018
Q4 		$366K Buy
58,069
+317
+0.5% +$4K ﹤0.01% 3625
2018
Q3 		$1.01M Buy
+57,752
New +$952K ﹤0.01% 3465

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust's AQST Position: Q1 2026 in Review

Northern Trust reduced its Aquestive Therapeutics (AQST) stake by 1.4% in Q1 2026, selling an estimated $41.8K and leaving 732,504 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

Northern Trust first reported a position in AQST in Q3 2018 and has held it in 31 quarters since. The position peaked at $4.8M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Northern Trust held 732,504 shares of Aquestive Therapeutics worth $3.04M as of Q1 2026.
  • Northern Trust sold 10,290 Aquestive Therapeutics shares in Q1 2026, an estimated $41.8K.
  • Aquestive Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2736 holding.
  • Northern Trust first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • Northern Trust's Aquestive Therapeutics position peaked at $4.8M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.